Gyre Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Gyre Therapeutics, Inc. (GYRE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 10.95 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-03-13
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-06-30 was 2.56K shares, a 150.74% increase year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-03-31 was 12.17K shares, a 73.63% decline year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 10.95K shares.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 47.32K shares, a 7879.60% increase from fiscal 2021.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2021 was 593.00 shares, a 96.69% decline from fiscal 2020.
- Gyre Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2020 was 17.93K shares, a 57.35% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2025-12-31 | 10.95K shares 10-K · filed 2026-03-13 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | 2.56K shares derived: sum of 2 quarters · filed 2023-10-26 | 14.73K shares 10-Q · filed 2023-10-26 | 14.73K shares derived: sum of 4 quarters · filed 2023-10-26 |
| 2023-06-30 | 2.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | 14.73K shares 10-Q · filed 2023-08-14 | 14.73K shares derived: sum of 3 quarters · filed 2023-08-14 | 14.86K shares derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | 12.17K shares 10-Q · filed 2023-05-15 | 12.17K shares derived: sum of 2 quarters · filed 2023-05-15 | 12.30K shares derived: sum of 3 quarters · filed 2023-05-15 | 13.32K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 127.00 shares derived: sum of 2 quarters · filed 2023-03-30 | 1.15K shares derived: sum of 3 quarters · filed 2023-03-30 | 47.32K shares 10-K · filed 2023-03-30 |
| 2022-09-30 | 127.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 1.15K shares derived: sum of 2 quarters · filed 2022-11-14 | 47.32K shares 10-Q · filed 2022-11-14 | 47.34K shares derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | 1.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | 47.19K shares 10-Q · filed 2022-08-15 | 47.22K shares derived: sum of 3 quarters · filed 2022-08-15 | 47.22K shares derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | 46.17K shares 10-Q · filed 2022-05-09 | 46.20K shares derived: sum of 2 quarters · filed 2022-05-09 | 46.20K shares derived: sum of 3 quarters · filed 2022-05-09 | |
| 2021-12-31 | 24.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 24.00 shares derived: sum of 2 quarters · filed 2022-03-31 | 593.00 shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | 569.00 shares 10-Q · filed 2021-11-12 | ||
| 2021-06-30 | 569.00 shares 10-Q · filed 2021-08-05 | |||
| 2020-12-31 | 1.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 13.18K shares derived: sum of 2 quarters · filed 2022-03-31 | 14.01K shares derived: sum of 3 quarters · filed 2022-03-31 | 17.93K shares 10-K · filed 2022-03-31 |
| 2020-09-30 | 11.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 12.42K shares derived: sum of 2 quarters · filed 2020-11-05 | 16.34K shares 10-Q · filed 2020-11-05 | 17.03K shares derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-06-30 | 833.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 4.75K shares 10-Q · filed 2020-08-06 | 5.45K shares derived: sum of 3 quarters · filed 2021-03-04 | 8.67K shares derived: sum of 4 quarters · filed 2021-03-04 |
| 2020-03-31 | 3.92K shares 10-Q · filed 2020-05-11 | 4.62K shares derived: sum of 2 quarters · filed 2021-03-04 | 7.84K shares derived: sum of 3 quarters · filed 2021-03-04 | 9.67K shares derived: sum of 4 quarters · filed 2021-03-04 |
| 2019-12-31 | 697.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | 3.92K shares derived: sum of 2 quarters · filed 2021-03-04 | 5.75K shares derived: sum of 3 quarters · filed 2021-03-04 | 11.39K shares 10-K · filed 2021-03-04 |
| 2019-09-30 | 3.22K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | 5.06K shares derived: sum of 2 quarters · filed 2019-11-07 | 10.70K shares 10-Q · filed 2019-11-07 | 10.81K shares derived: sum of 4 quarters · filed 2020-02-20 |
| 2019-06-30 | 1.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | 7.47K shares 10-Q · filed 2019-08-01 | 7.59K shares derived: sum of 3 quarters · filed 2020-02-20 | 22.11K shares derived: sum of 4 quarters · filed 2020-02-20 |
| 2019-03-31 | 5.64K shares 10-Q · filed 2019-05-02 | 5.76K shares derived: sum of 2 quarters · filed 2020-02-20 | 20.28K shares derived: sum of 3 quarters · filed 2020-02-20 | |
| 2018-12-31 | 116.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-20 | 14.64K shares derived: sum of 2 quarters · filed 2020-02-20 | 15.78K shares 10-K · filed 2020-02-20 | |
| 2018-09-30 | 14.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | 15.67K shares 10-Q · filed 2018-11-01 | ||
| 2018-06-30 | 1.15K shares 10-Q · filed 2018-08-02 | |||
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-19 | 0.00 shares derived: sum of 2 quarters · filed 2018-03-19 | 141.00 shares 10-K · filed 2018-03-19 | |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | 141.00 shares 10-Q · filed 2017-11-02 | ||
| 2017-06-30 | 141.00 shares 10-Q · filed 2017-08-03 | |||
| 2016-12-31 | 13.77K shares 10-K · filed 2018-03-19 | |||
| 2015-12-31 | 7.12K shares 10-K · filed 2017-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |